Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

European Sickle Cell Disease Cohort - Hydroxyurea (ESCORT-HU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02516579
Recruitment Status : Completed
First Posted : August 6, 2015
Last Update Posted : August 6, 2019
Information provided by (Responsible Party):

Brief Summary:
In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in patients with Sickle Cell Disease.

Condition or disease Intervention/treatment
Sickle Cell Disease Drug: Siklos

Layout table for study information
Study Type : Observational
Actual Enrollment : 1928 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea
Study Start Date : January 2009
Actual Primary Completion Date : March 20, 2019
Actual Study Completion Date : March 20, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Hydroxyurea

Intervention Details:
  • Drug: Siklos
    Other Name: hydrocarbamide

Primary Outcome Measures :
  1. Occurence of adverse events and serious adverse events, specifically: - Frequency of maligancies - Frequency of skin ulceration (broken out by severity) - Frequency of myelosuppression requiring temporary or permanent discontinuation of Siklos [ Time Frame: up to 1 year follow-up ]

Secondary Outcome Measures :
  1. Effects of Siklos on growth development: specific examinations (scintigraphy, radiography,...) if the difference with the normal growth is upper than 2 standard deviations [ Time Frame: up to 1 year follow-up ]
  2. Outcome of pregnancies: rates of miscarriage, stillbirths, APGAR score at birth, congenital malformations [ Time Frame: up to 1 year follow-up ]
  3. Any occurrence of an unforeseen safety pattern [ Time Frame: up to 1 year follow-up ]

Other Outcome Measures:
  1. Overall mortality and survival rates [ Time Frame: up to 1 year follow-up ]
  2. Frequency of vaso-occlusive complications (painful crises, acute chest syndrome, stroke, acute splenic sequestration and infections) [ Time Frame: up to 1 year follow-up ]
  3. Hospitalisation due to SCD events [ Time Frame: up to 1 year follow-up ]
  4. Frequency of blood transfusions [ Time Frame: up to 1 year follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with sickle-cell disease

Inclusion Criteria:

  • Male or female ambulatory patients, aged 2 years and more (children, adolescents or adults)
  • With symptomatic sickle cell syndrome
  • Treated with Siklos®
  • Having been informed of the study by the initiating physician and consenting to participate to the cohort.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02516579

Show Show 60 study locations
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Frédéric Galacteros, MD Hôpital henri Mondor (Adults)
Principal Investigator: Mariane de Montalembert, MD Hôpital Necker Enfants Malades (Children)

Layout table for additonal information
Responsible Party: ADDMEDICA SASA Identifier: NCT02516579    
Other Study ID Numbers: ESCORT-HU
First Posted: August 6, 2015    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Antineoplastic Agents
Antisickling Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors